Krónikus mieloid leukémia (CML): vizsgálatok itt: Olaszország
19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Padova, Roma
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Genoa, Meldola, Milan, Pisa, Rome, Turin
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 1/2. fázisTaking peopleA Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
- Where
- Bologna, Milan, Monza
- Életkor
- 18 év to 64 év
- People
- 330 worldwide
- Run by
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00 - 1/2. fázisTaking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
- Életkor
- 1 év to 17 év
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - 2/3. fázisTaking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Bologna, Florence, Milan, Novara, Ravenna, Rome, Turin
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - 4. fázisTaking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
- Életkor
- 18 év and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00 - 2. fázisTaking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Bologna, Florence, Salerno, Verona
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - 3. fázisTaking peopleStudy of Olverembatinib (HQP1351) in Patients With CML-CP
- Where
- Bologna, Candiolo, Catania, Lecce, Meldola, Messina, Milan, Naples, Novara, Padova, Pisa, Rome, Turin, Varese
- Életkor
- 18 év and over
- People
- 333 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00 - 2. fázisTaking peopleStudy to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
- Where
- Padova, Rome
- Életkor
- Up to 17 év
- People
- 16 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522138-29-00 · EU 2025-522138-29-00 - No phaseTaking peopleA Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
- Where
- Reggio Emilia
- Életkor
- 18 év to 75 év
- People
- 350
- Run by
- Azienda USL Reggio Emilia - IRCCS
See details and how to joinNCT07061145 - 2. fázisCsak meghívásosA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Milan
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 1/2. fázisNot yet taking people in OlaszországA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Bologna, Naples, Padova, Pavia, Rozzano
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - No phaseNot yet taking people in OlaszországENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
- Where
- Torino
- Életkor
- 18 év and over
- People
- 25
- Run by
- Carmen Fava
See details and how to joinNCT07518940 - 1. fázisTaking peopleA Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Where
- Ancona
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Enliven Therapeutics
See details and how to joinNCT05304377 · EU 2023-503335-18-00 - No phaseTaking peopleQuality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
- Where
- Monza
- Életkor
- 18 év and over
- People
- 2000
- Run by
- University of Milano Bicocca
See details and how to joinNCT07165535 - 2. fázisTaking peoplePEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
- Where
- Ancona, Bari, Bologna, Brescia, Catania, Florence, Messina, Milan, Naples, Novara, Padova, Palermo, Pavia, Piacenza, Reggio Calabria, Reggio Emilia, Rome, Siena, Turin, Udine, Verona, Vicenza, ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT06409936 · EU 2024-512696-12-00 - No phaseTaking peoplePonatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
- Where
- Cagliari, Milan, Naples, Pisa, Roma
- Életkor
- 18 év and over
- People
- 100
- Run by
- University of Pisa
See details and how to joinNCT06119269 - No phaseTaking peopleInteraction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
- Where
- Torino
- Életkor
- 18 év and over
- People
- 100
- Run by
- Carmen Fava
See details and how to joinNCT06724536 - No phaseTaking peopleItalian Treatment Free Remission Registry
- Where
- Turin
- Életkor
- 18 év and over
- People
- 800
- Run by
- University of Turin, Italy
See details and how to joinNCT04769947